The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
Open accessAbstract
Background Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.Methods This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0·90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2·5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants.Findings Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0·86, 95% CI 0·69-1·08, p=0·19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0·67, 95% CI 0·45-1·00, p=0·05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1·61, 95% CI 1·12-2·31, p=0·0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1·68, 95% CI 1·17-2·40; p=0·0043).Interpretation Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding.Funding Bayer AG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A study shared that low-dose rivaroxaban with aspirin reduced major adverse cardiovascular and limb events compared with aspirin alone without significantly increasing major bleeding [82].”
From Revascularization Strategies for Acute and Chronic Mesenteric Ischemia: A Narrative Review (2024) · cites this paper as [82]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There was an associated increased risk of bleeding with rivaroxaban, although no significant excess in fatal bleeding was noted.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [58]
In the citing paper
“a review of 56 studies including patients with diabetes suggested higher limbsalvage rates after revascularization (78-85% at 1 year) compared with conservative management.768”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [768]
In the citing paper
“The risk of major adverse cardiovascular events (MACEs) was significantly lower with the combination of rivaroxaban plus aspirin compared with either aspirin alone or rivaroxaban alone.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [58]
In the citing paper
“The ischemic benefits of rivaroxaban were consistent in the subgroup with diabetes mellitus, suggesting that low-dose anticoagulation added to antiplatelet therapy may be another option for secondary prevention in patients with T2DM and stable CAD.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationClopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,819
Self-citationRivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Self-citationRivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J., Bhatt, D. L., Bode, C., Burton, P. B. J., Cohen, M. C., Cook‐Bruns, N., Fox, K. A. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,923
Self-citationESC Guidelines on the diagnosis and treatment of peripheral artery diseases
Endorsed by: the European Stroke Organisation (ESO), Authors/Task Force Members, Tendera, M., Aboyans, V., Bartelink, M.-L., Baumgartner, I., Clément, D., Collet, J.-P., Cremonesi, A., De Carlo, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr211 · Cited by 1,506
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Self-citationOne-year cardiovascular event rates in outpatients with atherothrombosis
Steg, P. G., Bhatt, D. L., Wilson, P. W. F., D’Agostino, R., Ohman, E. M., Röther, J., Liau, C.-S., Hirsch, A. T., Mas, J.-L., Ikeda, Y., et al. (2007) · JAMA · doi:10.1001/jama.297.11.1197 · Cited by 1,382
Self-citationGerhard‐Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000471 · Cited by 1,048
Brott, T. G., Halperin, J. L., Abbara, S., Bacharach, J. M., Barr, J. D., Bush, R. L., Cates, C. U., Creager, M. A., Fowler, S. A., Friday, G. H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820d8d78 · Cited by 801
Self-citationConnolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32458-3 · Cited by 754
Self-citation
Research works printed but not linked: 2
- 1996, A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE), Lancet, 348, 329
- Connolly, 2017, Rivaroxaban in stable coronary disease, Lancet
Cited by
Sorted by citations
Items 601–700 of 877
Lipoprotein(a), Peripheral Artery Disease, and Abdominal Aortic Aneurysm
Beckman, J. A., & Sullivan, A. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.015 · Cited by 3
The role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era
Vogt, J. C., Manning, P. G., Sheikh, O., Aronow, H. D., CHILTON, R. J., & Cigarroa, J. E. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29089 · Cited by 1
“PAD was a major enrollment criterion, and a prespecified subgroup analysis was planned.(48) Enrollment for PAD required a history of lower extremity (LE) revascularization, prior limb or foot amputation for PAD, or intermittent claudication (IC) with”
Self-citationThe new Epoch of Antithrombotic Therapy in the Long-Term Prevention of a non-Cardioembolic Stroke
Fonyakin, A. V., & Гераскина, Л. А. (2021) · Kardiologiia · doi:10.18087/cardio.2020.12.n1032 · Cited by 1
Freeman, S. V., Williams, P., Barón, A. E., Plomondon, M. E., & Waldo, S. W. (2022) · International Journal of Vascular Medicine · doi:10.1155/2022/3786815 · Cited by 1
“Surgical Limb Revascularization for PAD (VOYAGER PAD) and the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) both demonstrating benefits with the use of rivaroxaban [7, 8].”
BackgroundMethodResultInfluentialLow-dose aspirin for the prevention of atherothrombosis across the cardiovascular risk continuum
Walker, J. (2022) · Cardiology Plus · doi:10.1097/cp9.0000000000000017 · Cited by 1
Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patient
Gargiulo, G., & Esposito, G. (2022) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2022.2391 · Cited by 1
Возможности гибридных технологий в лечении подвздошно-бедренных окклюзий
Папоян, С. А., Щеголев, А. А., Maytesyan, D., Абрамов, И. С., Сыромятников, Д. Д., Sazonov, M. Y., & Мутаев, М. М. (2022) · Russian Journal of Thoracic and Cardiovascular Surgery · doi:10.24022/0236-2791-2022-64-5-508-516 · Cited by 2
Hemostatic abnormalities associated with diabetes and their clinical implications
Kietsiriroje, N., Ajjan, R., & Grant, P. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00005-x · Cited by 1
Yu, Q., Chen, C., Cao, J., Xu, J., Lu, J., & Yuan, L. (2023) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2023.11.005 · Cited by 1
The state of evidence for the daily routine intervention for carotid artery stenosis
Abbott, A. L. (2024) · Gefässchirurgie · doi:10.1007/s00772-024-01151-3 · Cited by 1
Rivaroxaban plus aspirin after lower–extremity revascularization
McClure, G. R., & Eikelboom, J. W. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2432358 · Cited by 1
“In this population, the combination of rivaroxaban and aspirin compared to aspirin alone reduced both MACE (HR 0.72, 95% CI 0.57–0.90, p = 0.0047) and MALE (HR 0.54 95% CI 0.35–0.82, p = 0.0037) [9].”
InfluentialSelf-citationDörr, G. (2024) · Die Rehabilitation · doi:10.1055/a-2154-3672 · Cited by 1
Dual pathway inhibition in patients with peripheral artery disease in Germany
Herold, J., Dagkonakis, N., Debus, E. S., Rauch‐Kröhnert, U., Zeymer, U., & Bauersachs, R. M. (2025) · VASA · doi:10.1024/0301-1526/a001174 · Cited by 1
Goudarzi, Z., Najafpour, Z., Gholami, A., Keshavarz, K., Mojahedian, M. M., & Babayi, M. M. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-12431-3 · Cited by 4
“Besides, they were assumed not to receive dual antiplatelet, anticoagulant, or other antithrombotic therapy with no cardiovascular conditions related to a poor prognosis [19–21].”
InfluentialWells, N., Alameddine, D., Dhanda, U., Tran, L. J., Silva, D., Slade, M. D., Guzman, R. J., & Chaar, C. I. O. (2025) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2025.03.183 · Cited by 1
Self-citationPredicting Outcomes Following Carotid Artery Stenting Using Machine Learning
Li, B., Aljabri, B. A., Beaton, D., Hussain, M. A., Lee, D. S., Wijeysundera, D. N., Rotstein, O. D., de Mestral, C., Mamdani, M., Roche‐Nagle, G., et al. (2025) · Journal of Endovascular Therapy · doi:10.1177/15266028251333670 · Cited by 1
Antiplatelet and Anticoagulation Therapy for Peripheral Arterial Disease: Risks Versus Benefits
Kim, D., Shah, S. K., Trivedi, D. B., Parikh, M. A., Jackson, K. A., Frishman, W. H., & Peterson, S. J. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000956 · Cited by 1
Self-citationErfanifar, A., Jahanian, A., Fathy, M., Abbasi, M., Gachkar, L., & Kalbasi, S. (2025) · International Cardivascular Research Journal · doi:10.5812/icrj-154736 · Cited by 1
“Nonetheless, the effects of the combination of ASA and rivaroxaban on the clinical presentations of PAD before revascularization have not been established (21).”
Gefäßmedizinische Rehabilitation bei Patienten mit peripher arterieller Verschlusskrankheit (pAVK)
Dörr, G. (2025) · Physikalische Medizin Rehabilitationsmedizin Kurortmedizin · doi:10.1055/a-2520-7961 · Cited by 1
Korompoki, E., Ntaios, G., Sagris, D., Vemmos, K. N., & Veltkamp, R. C. (2025) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2025.07.004 · Cited by 1
Extrakranielle Karotisstenose: Prävalenz, Diagnostik und Therapie
Andrassy, M., Zeller, T., Langhoff, R., Rammos, C., Tiefenbacher, C., Dahm, J. B., Marx, N., & Korosoglou, G. (2025) · Die Kardiologie · doi:10.1007/s12181-025-00768-2 · Cited by 1
Zhang, G., Liu, X.-C., Li, J.-C., Zhao, Y., Yuan, Z., Chen, Y., Zhang, S.-K., Chang, M., Jin, L.-L., Tao, C., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1592322 · Cited by 2
Self-citationGoedegebuur, J., Butera, E., Chen, Q., Bikdeli, B., Ageno, W., Pola, R., Porfidia, A., Barco, S., van Mens, T. E., van der Vorst, J. R., et al. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.103291 · Cited by 1
“Earlier studies have suggested the efficacy of low-dose rivaroxaban in combination with aspirin in the prevention of arterial thromboembolic events [22,27], however, they lack generalizability [31,32] and do not compare aspirin and add-on DOAC with P2Y12 inhibitors, while the P2Y12 inhibitors seem…”
InfluentialGoodney, P. P., Ross, E., Bruckel, J. T., Alabi, O., Altin, S. E., Bauer, K. L., Diekemper, R. L., Gerhard‐Herman, M. D., Johnston, L. E., Martin, V. T., et al. (2026) · Circulation Population Health and Outcomes · doi:10.1161/hcq.0000000000000142 · Cited by 1
Multani, A., Chowdhary, R., Schulman, Z., Reddy, M., Rosenzveig, A., Dixit, S., Multani, A., Wu, T., Dieter, R. S., & Nanjundappa, A. (2026) · International Journal of Angiology · doi:10.1055/a-2798-9516 · Cited by 1
Physical Therapist Management of Cardiovascular Diseases
Ahmed, A. S., Balogun, J. A., & Balogun, O. I. (2026) · Springer eBooks · doi:10.1007/978-3-031-86558-9_21 · Cited by 1
Hofmann, M., Lachat, M. L., Palma, A., & Chaykovska, L. (2026) · Journal of Vascular Surgery Cases and Innovative Techniques · doi:10.1016/j.jvscit.2026.102225 · Cited by 1
Gouda, P., Secemsky, E. A., Hess, C. N., Arya, S., Fokorede, F., Mehran, R., Bonaca, M. P., Patel, M. R., & Jones, W. S. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107446 · Cited by 1
D’Oria, M., Zlatanović, P., Rocha-Neves, J. P., Paulo-Castro, J., Fernandes, R., GALEGO, C., Stevanovic, K. S., Novakovic, T., Loureiro, L., Giacomelli, E., et al. (2026) · International Angiology · doi:10.23736/s0392-9590.26.05478-7 · Cited by 1
Rivaroxaban for Cardiovascular Disease Prevention in Chronic Kidney Disease
Bansal, N., & Winkelmayer, W. C. (2026) · JAMA · doi:10.1001/jama.2026.9780 · Cited by 1
Marzano, A., Florà, F., Silvestri, O., Chiara, M. S. D., Barbarisi, D., Gallicchio, V., Flora, L., di Marzo, L., Peluso, A., & Mansour, W. (2026) · Biomedicines · doi:10.3390/biomedicines14071538 · Cited by 3
“After technically successful recanalization, all patients in both groups received antithrombotic therapy according to the VOYAGER PAD regimen, consisting of acetylsalicylic acid 100 mg once daily plus rivaroxaban 2.5 mg twice daily [22,23].”
InfluentialTulamo, R. M., Bradbury, A., Hicks, C. W., Gottsäter, A., Gupta, P. C., Rother, U., Sigvant, B., & Hinchliffe, R. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00845-7 · Cited by 2
Chon, S. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.1.24 · Cited by 1
Current and Emerging Therapies for Atherosclerosis
Nelson, A. J., & Nicholls, S. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-43683-4_4 · Cited by 2
Kataruka, A., Mahtta, D., Akeroyd, J. M., Hira, R. S., Kazi, D. S., Spertus, J. A., Bhatt, D. L., Petersen, L. A., Ballantyne, C. M., & Virani, S. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07061-2 · Cited by 3
Self-citationŠustr, F., & Souček, M. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.050 · Cited by 1
Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit
Debus, E. S., Espinola–Klein, C., Honig, S., Behrendt, C., & Bauersachs, R. M. (2021) · Gefässchirurgie · doi:10.1007/s00772-021-00786-w · Cited by 1
Kosayev, J. V., Hasanov, I. A., Abushov, N. S., & Taghi-zade, G. T. (2021) · Laser Medicine · doi:10.37895/2071-8004-2021-25-1-27-35 · Cited by 1
Arustamyan, V. A., Михайлов, И. П., Demyanov, A. M., & Валерьевна, Л. О. (2021) · Kreativnaya kardiologiya · doi:10.24022/1997-3187-2021-15-2-268-277 · Cited by 1
Skeik, N., Jordano, L., Robinson, E. C., Mirza, A. K., & Manunga, J. M. (2022) · Angiology · doi:10.1177/00033197211048596 · Cited by 2
“90]).(28) In addition, the PAD or carotid disease subgroup experienced fewer MALE in the rivaroxaban plus aspirin arm than in the aspirin-alone arm (1.”
BackgroundLi, C., Carroll, B., & Schermerhorn, M. L. (2018) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2018.07.002 · Cited by 1
“The 2009 American College of Cardiology Foundation/ American Heart Association guidelines recommend perioperative continuation of beta blockers and preoperative initiation of beta blockers in patients with high cardiac risk.2 However, pivotal trials demonstrating benefit of perioperative beta blockers have been retrac…”
Self-citationClinical experience with dual pathway inhibition therapy: case series and mini review
Geisler, T., Branch, K. R., & Nikol, S. (2022) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytac201 · Cited by 1
“The risk of major bleeding, but not intracranial or fatal bleeding, was significantly increased with DPI versus aspirin alone.(3,4) The benefit–risk profile of DPI was favourable across subgroups in the COMPASS study, and those with the highest absolute risk of ischaemic events were shown to benefit most from DPI.”
BackgroundMethodSelf-citationKeohane, C. R., Westby, D., Twyford, M., Ahern, T., Tawfick, W. A., & Walsh, S. R. (2022) · Trials · doi:10.1186/s13063-022-06440-4 · Cited by 1
“Therefore, many guidelines only recommend surgery as a means to reduce recurrence [10].”
BackgroundKumar, R., & Bainey, K. R. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.06.1022 · Cited by 1
Self-citationBalletshofer, B. M., Böckler, D., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., Malyar, N. M., Qiu, H. J., Reimer, P., et al. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1908-0612 · Cited by 1
Rivaroxaban With or Without Aspirin in Patients with Stable Peripheral or Carotid Artery Disease
Shakarchi, J. A. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197637906.003.0002 · Cited by 1
Wille, H. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_9 · Cited by 1
Bendary, A., Zarif, B., Badran, H. M., Shokry, K., & Kabil, H. (2023) · The Egyptian Heart Journal · doi:10.1186/s43044-023-00364-3 · Cited by 1
Advances in Antithrombotic Therapy for Peripheral Artery Diseases
陈, 媛. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1371596 · Cited by 1
Thromboembolische Erkrankungen aus angiologischer Sicht
Linnemann, B., & Espinola–Klein, C. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1825-7033 · Cited by 1
“siko für akute Extremitätenischämie und Majoramputationen gegenüber alleiniger ASS-Therapie signifikant zu senken [13, 14, 15].”
Lee, C., Ramkumar, N., Young, M. N., Goodney, P. P., Creager, M. A., & Henkin, S. (2023) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2023.08.099 · Cited by 1
Interventionelle Therapie der peripheren arteriellen Verschlusskrankheit
Böhme, T., & Zeller, T. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2017-7786 · Cited by 1
“Die Rolle einer zusätzlichen, niedrig dosierten oralen Antikoagula-tion, mit neuen Antikoagulanzien wie Rivaroxaban 2× 2,5 mg, ist noch nicht abschließend geklärt, auch wenn Studien bei AVK-Patienten unabhängig von einer Revas-kularisation positive klinische Ergebnisse erbrachten [27, 28].”
BackgroundBalletshofer, B. M., Böckler, D., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., Malyar, N. M., Qiu, H. J., Reimer, P., et al. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2076-0248 · Cited by 1
Chronic critical limb ischemia (CLTI)
Chochola, M. (2023) · Vnitřní lékařství · doi:10.36290/vnl.2023.083 · Cited by 1
Iannuzzi, J. C., & Conte, M. S. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_35 · Cited by 1
Bucci, T., Sole, F. D., Menichelli, D., Galardo, G., Biccirè, F. G., Farcomeni, A., Lip, G. Y. H., Pignatelli, P., & Pastori, D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072033 · Cited by 2
“In these analyses, instead of considering the original COMPASS study [12], we incorporated two different post hoc analyses that specifically addressed the risk of adverse events in CAD [20] or PAD [31] patients.”
MethodMedical Optimization of Patients with Symptomatic Peripheral Arterial Disease
Abumoawad, A., Okazaki, R. A., Behrooz, L., & Eberhardt, R. T. (2024) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2024.01.027 · Cited by 1
Periphere arterielle Verschlusskrankheit (pAVK)
Espinola–Klein, C. (2024) · Herz · doi:10.1007/s00059-024-05252-3 · Cited by 1
Baker, D., Cruddas, L., Eveson, T., Bakhai, A., & Penge, J. (2024) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2024.05.018 · Cited by 1
“…reduction from 6 to 3.9%, P ¼ 0.07) 2 with no increase in major bleeding side effects (1.9 e 2.3% P ¼ 0.67) 2 We also adopted the COMPASS trial 1,2,23 recommendations as it demonstrated reduced MACE (stoke, cardiac, and peripheral vascular) in patients with known atherosclerotic disease (stable…”
InfluentialBuso, G., Lanzi, S., Berchtold, A., Déglise, S., Alatri, A., Calanca, L., & Mazzolai, L. (2024) · VASA · doi:10.1024/0301-1526/a001139 · Cited by 1
Cardiometabolic diseases—Recent advance in antithrombotic and thrombolytic therapies
Nikolovski, S. S., Jeske, W. P., & Fareed, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00006-1 · Cited by 1
Balletshofer, B. M., Böckler, D., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., Malyar, N. M., Qiu, H. J., Reimer, P., et al. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-0680 · Cited by 1
Li, W., Li, Y., Liu, C., Yuan, J., Fan, W.-Z., Miao, Q., & Gu, X. (2024) · Medical Science Monitor · doi:10.12659/msm.945457 · Cited by 1
Acute Limb Ischemia Interventions
Ahmed, A., Naeem, N., Jain, A., Arora, S. M. S., & Elgendy, I. Y. (2025) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2024.11.012 · Cited by 2
Harish, K. B., Chervonski, E., Rokosh, R. S., Garg, K., Berland, T. L., Sadek, M., Teter, K., Rockman, C. R., Jacobowitz, G. R., & Maldonado, T. S. (2025) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2025.04.022 · Cited by 1
Li, H., Wang, T., Wang, J., Cheng, F., Wang, L., & Wang, H. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109414 · Cited by 1
Rivaroxaban plus aspirin in CAD or PAD
Lim, G. B. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.192 · Cited by 1
ABI: The goal line is in sight
Beckman, J. A. (2018) · Vascular Medicine · doi:10.1177/1358863x17749300 · Cited by 1
Rivaroxaban with or without aspirin for prevention of cardiovascular disease
Kruger, P. C., Eikelboom, J. W., & Yusuf, S. (2018) · Coronary Artery Disease · doi:10.1097/mca.0000000000000605 · Cited by 1
Self-citationAntiplatelet Drugs in the Management of Thrombotic/Ischemic Events in Peripheral Artery Disease
Basili, S., & Violi, F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00058-8 · Cited by 1
Imaging Needs for Development of Novel Therapeutics in PAD
Kaso, E. R., & Annex, B. H. (2019) · Springer eBooks · doi:10.1007/978-3-030-24596-2_7 · Cited by 1
Formiga, F., Montero, A., & Lopez-Carmona, M. D. (2020) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2020.02.003 · Cited by 1
Thrombozytenaggregationshemmung (TAH) und orale Antikoagulation (OAK)
Süss, J. D., & Gawenda, M. (2020) · Gefässchirurgie · doi:10.1007/s00772-020-00633-4 · Cited by 1
Fanelli, F. (2020) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-020-02524-3 · Cited by 1
Savonitto, S., Pelizzoli, S., & Selva, A. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa079 · Cited by 1
“Of great interest was the evaluation of MALE which included acute ischaemic events affecting the limbs and peripheral amputations.(19) Despite the very high-risk characteristics of the population, and despite the fact that around 25% of patients persisted in the smoking habit, the total risk of MALE, which included ac…”
BackgroundMethodInfluentialGerhard‐Herman, M. D., & Aday, A. W. (2020) · Springer eBooks · doi:10.1007/978-3-030-44715-1_3 · Cited by 1
Recent advances in preventing recurrent stroke
Spence, J. D. (2020) · F1000Research · doi:10.12688/f1000research.23199.1 · Cited by 1
Current concepts of anticoagulant and antiplatelet therapy in patients with vascular pathology
Sapelkin, S. V., & Kuznetsov, M. R. (2020) · Angiology and vascular surgery · doi:10.33529/angi02020305 · Cited by 1
Periphere arterielle Verschlusskrankheit (pAVK)
Müller, O. J. (2020) · e Curriculum Innere Medizin · doi:10.1007/s40531-020-00040-0 · Cited by 1
Features of Antithrombotic Therapy in Patients with Multifocal Arterial Disease
Геннадьевич, Г. В., Сергеевна, В. С., & Smolenskaya, O. G. (2021) · Kardiologiia · doi:10.18087/cardio.2021.3.n1498 · Cited by 1
Considerations for use of direct oral anticoagulants in arterial disease
Siegal, D. M., & Anand, S. S. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12502 · Cited by 2
Self-citationPrevention of ischaemic events in subjects with polydistrict vascular disease
Patti, G., & Ghiglieno, C. (2021) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab102 · Cited by 1
“9% decrease in the absolute risk of net clinical endpoint including cardiovascular death, stroke, MI, acute limb ischaemia, vascular amputation, fatal, or symptomatic major organ bleeding.(3,9,11) Finally, it is appropriate to underline how many conditions associated with an increased thrombotic risk can also predispo…”
BackgroundWillems, L. H., Thijssen, D., Donders, A. R. T., van der Vijver-Coppen, R. J., Groh, L., Reijnen, M. M. P. J., & Warlé, M. (2021) · Medicine Case Reports and Study Protocols · doi:10.1097/md9.0000000000000163 · Cited by 2
Moosavi, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-80915-3.00010-7 · Cited by 1
How to optimize treatment in patients with different forms of coronary artery disease
Gilyarov, M. Y., & Константинова, Е. В. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-6-273-279 · Cited by 1
Vascular Disease and Venous Thromboembolism
Lakhter, V., Giri, J. S., & Garasic, J. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_13 · Cited by 1
Balletshofer, B. M., Böckler, D., die, D. G. G., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., die, D. G. A., Malyar, N. M., et al. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00741-z · Cited by 1
Sidebottom, D. B., Huang, C., Carradice, D., Holt, P., John-Pierre, K., & Roy, I. N. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072355
Sagris, Μ., Theofilis, P., Papanikolaou, A., Antonopoulos, A. S., Tsioufis, C., & Tousoulis, D. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128259508231118141831 · Cited by 1
Kumar, A. (2023) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v4i12.978
Larena-Avellaneda, A. A. (2018) · Gefässchirurgie · doi:10.1007/s00772-018-0367-y · Cited by 1
“die Beeinflussung derselben auch bei stabiler peripherer arterieller Verschlusskrankheit oder Karotisstenose die Prognose unserer Patienten quod vitam verändert [1].”
BackgroundPeripheral arterial disease and limb salvage: a new arena for the cardiologist
Lewis, B. S., & Atar, D. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy014 · Cited by 1
Self-citationCost-effectiveness analysis: A tool in the hands of the clinician
Carlo, M. D. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487318822357 · Cited by 1
“Importantly, the COMPASS sub-analysis in patients with PAD (including symptomatic LEAD, carotid artery disease, and CAD with asymptomatic LEAD) demonstrated a highly significant 28% reduction in the primary end point as well as a 46% reduction in major adverse limb events (acute and chronic limb ischaemia including ma…”
MethodBode, C., Olivier, C. B., & Duerschmied, D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.066 · Cited by 1
Zhao, T., Chen, Y., Dalong, W., Wang, L., Dong, P., Zhao, S. M. Z., Wang, C., Meng, Q., Sun, H., Liu, K., et al. (2020) · doi:10.22541/au.160157601.16885644 · Cited by 1
Self-citationMedical Management of Peripheral Arterial Disease
Conde, I. D., & Baumann, F. (2022) · Techniques in vascular and interventional radiology · doi:10.1016/j.tvir.2022.100837 · Cited by 2
Cicero, A. F. G., & Salvetti, M. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.06.1015 · Cited by 1
COMPASS-guided secondary prevention
Lim, G. B. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.184
Was bringt die duale Sekundärprävention bei PAVK und bei KHK?
Einecke, D. (2018) · CardioVasc · doi:10.1007/s15027-018-1319-x
Metadata
- Authors
- Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., Maggioni, A. P., Lewis, B. S., Störk, S., Zhu, J., Lopez-Jaramillo, P., O'Donnell, M., Commerford, P. J., Vinereanu, D., Pogosova, N., Ryden, L., Fox, K. A. A., Bhatt, D. L., Misselwitz, F., Varigos, J. D., Vanassche, T., Avezum, A. A., Chen, E., Branch, K., Leong, D. P., Bangdiwala, S. I., Hart, R. G., Yusuf, S., SALA, J., CARTASEGNA, L., VICO, M., HOMINAL, M. A., HASBANI, E., CACCAVO, A., ZAIDMAN, C., VOGEL, D., HRABAR, A., SCHYGIEL, P. O., CUNEO, C., LUQUEZ, H., MACKINNON, I. J., AHUAD GUERRERO, R. A., COSTABEL, J. P., BARTOLACCI, I. P., MONTANA, O., BARBIERI, M., GOMEZ VILAMAJO, O., GARCIA DURAN, R. O., SCHIAVI, L. B., GARRIDO, M., INGARAMO, A., BORDONAVA, A. P., PELAGAGGE, M. J., NOVARETTO, L., ALBISU DI GENNERO, J. P., IBANEZ SAGGIA, L. M., ALVAREZ, M., VITA, N. A., MACIN, S. M., DRAN, R. D., CARDONA, M., GUZMAN, L., SARJANOVICH, R. J., CUADRADO, J., NANI, S., LITVAK BRUNO, M. R., CHACON, C., MAFFEI, L. E., GRINFELD, D., VENSENTINI, N., MAJUL, C. R., LUCIARDI, H. L., GONZALEZ COLASO, P. D. C., FERRE PACORA, F. A., VAN DEN HEUVEL, P., VERHAMME, P., ECTOR, B., DEBONNAIRE, P., VAN DE BORNE, P., LEROY, J., SCHROE, H., VRANCKX, P., ELEGEERT, I., HOFFER, E., DUJARDIN, K., INDIO DO BRASIL, C., PRECOMA, D., ABRANTES, J. A., MANENTI, E., REIS, G., SARAIVA, J., MAIA, L., HERNANDES, M., ROSSI, P., ROSSI DOS SANTOS, F., ZIMMERMANN, S. L., RECH, R., ABIB JR, E., LEAES, P., BOTELHO, R., DUTRA, O., SOUZA, W., BRAILE, M., IZUKAWA, N., NICOLAU, J. C., TANAJURA, L. F., SERRANO JUNIOR, C. V., MINELLI, C., NASI, L. A., OLIVEIRA, L., DE CARVALHO CANTARELLI, M. J., TYTUS, R., PANDEY, S., LONN, E., CHA, J., VIZEL, S., BABAPULLE, M., LAMY, A., SAUNDERS, K., BERLINGIERI, J., KIAII, B., BHARGAVA, R., MEHTA, P., HILL, L., FELL, D., LAM, A., AL-QOOFI, F., BROWN, C., PETRELLA, R., RICCI, J. A., GLANZ, A., NOISEUX, N., BAINEY, K., MERALI, F., HEFFERNAN, M., DELLA SIEGA, A., DAGENAIS, G. R., DAGENAIS, F., BRULOTTE, S., NGUYEN, M., HARTLEIB, M., GUZMAN, R., BOURGEOIS, R., RUPKA, D., KHAYKIN, Y., GOSSELIN, G., HUYNH, T., PILON, C., CAMPEAU, J., PICHETTE, F., DIAZ, A., JOHNSTON, J., SHUKLE, P., HIRSCH, G., RHEAULT, P., CZARNECKI, W., ROY, A., NAWAZ, S., FREMES, S., SHUKLA, D., JANO, G., COBOS, J. L., CORBALAN, R., MEDINA, M., NAHUELPAN, L., RAFFO, C., PEREZ, L., POTTHOFF, S., STOCKINS, B., SEPULVEDA, P., PINCETTI, C., VEJAR, M., TIAN, H., WU, X., KE, Y., JIA, K., YIN, P., WANG, Z., YU, L., WU, S., WU, Z., LIU, S. W., BAI, X. J., ZHENG, Y., YANG, P., YANG, Y. M., ZHANG, J., GE, J., CHEN, X. P., LI, J., HU, T. H., ZHANG, R., ZHENG, Z., CHEN, X., TAO, L., LI, J., HUANG, W., FU, G., LI, C., DONG, Y., WANG, C., ZHOU, X., KONG, Y., SOTOMAYOR, A., ACCINI MENDOZA, J. L., CASTILLO, H., URINA, M., AROCA, G., PEREZ, M., MOLINA DE SALAZAR, D. I., SANCHEZ VALLEJO, G., FERNANDO, M. J., GARCIA, H., GARCIA, L. H., ARCOS, E., GOMEZ, J., CUERVO MILLAN, F., TRUJILLO DADA, F. A., VESGA, B., MORENO SILGADO, G. A., ZIDKOVA, E., LUBANDA, J.-C., KALETOVA, M., KRYZA, R., MARCINEK, G., RICHTER, M., SPINAR, J., MATUSKA, J., TESAK, M., MOTOVSKA, Z., BRANNY, M., MALY, J., MALY, M., WIENDL, M., FOLTYNOVA CAISOVA, L., SLABY, J., VOJTISEK, P., PIRK, J., SPINAROVA, L., BENESOVA, M., CANADYOVA, J., HOMZA, M., FLORIAN, J., POLASEK, R., COUFAL, Z., SKALNIKOVA, V., BRAT, R., BRTKO, M., JANSKY, P., LINDNER, J., MARCIAN, P., STRAKA, Z., TRETINA, M., DUARTE, Y. C., POW CHON LONG, F., SANCHEZ, M., LOPEZ, J., PERUGACHI, C., MARMOL, R., TRUJILLO, F., TERAN, P., TUOMILEHTO, J., TUOMILEHTO, H., TUOMINEN, M.-L., TUOMILEHTO, H., KANTOLA, I., STEG, G., ABOYANS, V., LECLERCQ, F., FERRARI, E., BOCCARA, F., MESSAS, E., MISMETTI, P., SEVESTRE, M. A., CAYLA, G., MOTREFF, P., STOERK, S., DUENGEN, H.-D., STELLBRINK, C., GUEROCAK, O., KADEL, C., BRAUN-DULLAEUS, R., JESERICH, M., OPITZ, C., VOEHRINGER, H.-F., APPEL, K.-F., WINKELMANN, B., DORSEL, T., NIKOL, S., DARIUS, H., RANFT, J., SCHELLONG, S., JUNGMAIR, W., DAVIERWALA, P., VORPAHL, M., BAJNOK, L., LASZLO, Z., NOORI, E., VERESS, G., VERTES, A., ZSARY, A., KIS, E., KORANYI, L., BAKAI, J., BODA, Z., POOR, F., JARAI, Z., KEMENY, V., BARTON, J., MCADAM, B., MURPHY, A., CREAN, P., MAHON, N., CURTIN, R., MACNEILL, B., DINNEEN, S., HALABI, M., ZIMLICHMAN, R., ZELTSER, D., TURGEMAN, Y., KLAINMAN, E., LEWIS, B., KATZ, A., ATAR, S., ZIMLICHMAN, R., NIKOLSKY, E., BOSI, S., NALDI, M., FAGGIANO, P., ROBBA, D., MOS, L., SINAGRA, G., COSMI, F., OLTRONA VISCONTI, L., CARMINE, D. M., DI PASQUALE, G., DI BIASE, M., MANDORLA, S., BERNARDINANGELI, M., PICCINNI, G. C., GULIZIA, M. M., GALVANI, M., VENTURI, F., MOROCUTTI, G., BALDIN, M. G., OLIVIERI, C., PERNA, G. P., CIRRINCIONE, V., KANNO, T., DAIDA, H., OZAKI, Y., MIYAMOTO, N., HIGASHIUE, S., DOMAE, H., HOSOKAWA, S., KOBAYASHI, H., KURAMOCHI, T., FUJII, K., MIZUTOMI, K., SAKU, K., KIMURA, K., HIGUCHI, Y., ABE, M., OKUDA, H., NODA, T., MITA, T., HIRAYAMA, A., ONAKA, H., INOKO, M., HIROKAMI, M., OKUBO, M., AKATSUKA, Y., IMAMAKI, M., KAMIYA, H., MANITA, M., HIMI, T., UENO, H., HISAMATSU, Y., AKO, J., NISHINO, Y., KAWAKAMI, H., YAMADA, Y., KORETSUNE, Y., YAMADA, T., YOSHIDA, T., SHIMOMURA, H., KINOSHITA, N., TAKAHASHI, A., YUSOFF, K., WAN AHMAD, W. A., ABU HASSAN, M. R., KASIM, S., ABDUL RAHIM, A. A., MOHD ZAMRIN, D., MACHIDA, M., HIGASHINO, Y., UTSU, N., NAKANO, A., NAKAMURA, S., HASHIMOTO, T., ANDO, K., SAKAMOTO, T., PRINS, F. J., LOK, D., MILHOUS, J. G.-J., VIERGEVER, E., WILLEMS, F., SWART, H., ALINGS, M., BREEDVELD, R., DE VRIES, K.-J., VAN DER BORGH, R., OEI, F., ZOET-NUGTEREN, S., KRAGTEN, H., HERRMAN, J. P., VAN BERGEN, P., GOSSELINK, M., HOEKSTRA, E., ZEGERS, E., RONNER, E., DEN HARTOG, F., BARTELS, G., NIEROP, P., VAN DER ZWAAN, C., VAN ECK, J., VAN GORSELEN, E., GROENEMEIJER, B., HOOGSLAG, P., DE GROOT, M. R., LOYOLA, A., SULIT, D. J., REY, N., ABOLA, M. T., MORALES, D., PALOMARES, E., ABAT, M. E., ROGELIO, G., CHUA, P., DEL PILAR, J. C., ALCARAZ, J. D., EBO, G., TIRADOR, L., CRUZ, J., ANONUEVO, J., PITARGUE, A., JANION, M., GUZIK, T., GAJOS, G., ZABOWKA, M., RYNKIEWICZ, A., BRONCEL, M., SZUBA, A., CZARNECKA, D., MAGA, P., STRAZHESKO, I., VASYUK, Y., SIZOVA, Z., POZDNYAKOV, Y., BARBARASH, O., VOEVODA, M., POPONINA, T., REPIN, A., OSIPOVA, I., EFREMUSHKINA, A., NOVIKOVA, N., AVERKOV, O., ZATEYSHCHIKOV, D., VERTKIN, A., AUSHEVA, A., COMMERFORD, P., SEEDAT, S., VAN ZYL, L., ENGELBRECHT, J., MAKOTOKO, E. M., PRETORIUS, C. E., MOHAMED, Z., HORAK, A., MABIN, T., KLUG, E., BAE, J.-H., KIM, C., KIM, C.-J., KIM, D.-S., KIM, Y. J., JOO, S., HA, J.-W., PARK, C. S., KIM, J. Y., KIM, Y.-K., JARNERT, C., MOOE, T., DELLBORG, M., TORSTENSSON, I., ALBERTSSON, P., JOHANSSON, L., AL-KHALILI, F., ALMROTH, H., ANDERSSON, T., PANTEV, E., TENGMARK, B.-O., LIU, B., RASMANIS, G., WAHLGREN, C.-M., MOCCETTI, T., PARKHOMENKO, A., TSELUYKO, V., VOLKOV, V., KOVAL, O., KONONENKO, L., PROKHOROV, O., VDOVYCHENKO, V., BAZYLEVYCH, A., RUDENKO, L., VIZIR, V., KARPENKO, O., MALYNOVSKY, Y., KOVAL, V., STOROZHUK, B., COTTON, J., VENKATARAMAN, A., MORIARTY, A., CONNOLLY, D., DAVEY, P., SENIOR, R., BIRDI, I., CALVERT, J., DONNELLY, P., TREVELYAN, J., CARTER, J., PEACE, A., AUSTIN, D., KUKREJA, N., HILTON, T., SRIVASTAVA, S., WALSH, R., FIELDS, R., HAKAS, J., PORTNAY, E., GOGIA, H., SALACATA, A., HUNTER, J. J., BACHARACH, J. M., SHAMMAS, N., SURESH, D., SCHNEIDER, R., GURBEL, P., BANERJEE, S., GRENA, P., BEDWELL, N., SLOAN, S., LUPOVITCH, S., SONI, A., GIBSON, K., SANGRIGOLI, R., MEHTA, R., I-HSUAN TSAI, P., GILLESPIE, E., DEMPSEY, S., HAMROFF, G., BLACK, R., LADER, E., KOSTIS, J. B., BITTNER, V., MCGUINN, W., BRANCH, K., MALHOTRA, V., MICHAELSON, S., VACANTE, M., MCCORMICK, M., ARIMIE, R., CAMP, A., DAGHER, G., KOSHY, N. M., THEW, S., COSTELLO, F., HEIMAN, M., CHILTON, R., MORAN, M., ADLER, F., COMEROTA, A., SEIWERT, A., FRENCH, W., SEROTA, H., HARRISON, R., BAKAEEN, F., OMER, S., CHANDRA, L., WHELAN, A., BOYLE, A., ROBERTS-THOMSON, P., ROGERS, J., CARROLL, P., COLQUHOUN, D., SHAW, J., BLOMBERY, P., AMERENA, J., HII, C., ROYSE, A., SINGH, B., SELVANAYAGAM, J., JANSEN, S., LO, W., HAMMETT, C., POULTER, R., NARASIMHAN, S., WIGGERS, H., NIELSEN, H., GISLASON, G., KOBER, L., HOULIND, K., BOENELYKKE SOERENSEN, V., DIXEN, U., REFSGAARD, J., ZEUTHEN, E., SOEGAARD, P., HRANAI, M., GASPAR, L., PELLA, D., HATALOVA, K., DROZDAKOVA, E., COMAN, I., DIMULESCU, D., VINEREANU, D., CINTEZA, M., SINESCU, C., ARSENESCU, C., BENEDEK, I., BOBESCU, E., DOBREANU, D., GAITA, D., IANCU, A., ILIESIU, A., LIGHEZAN, D., PETRESCU, L., PIRVU, O., TEODORESCU, I., TESLOIANU, D., VINTILA, M. M., & CHIONCEL, O.
- Affiliations
- Population Health Research Institute (CA)
- Charles University (CZ)
- Thrombosis Research Institute (GB)
- Semmelweis University (HU)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- University of Würzburg (DE)
- Fu Wai Hospital (CN)
- Ollscoil na Gaillimhe – University of Galway (IE)
- University of Edinburgh (GB)
- Brigham and Women's Hospital (US)
- Bayer (Germany) (DE)
- Monash University (AU)
- KU Leuven (BE)
- Bayer (United States) (US)
- Universidad Autónoma de Madrid (ES)
- Estudios Clínicos Latinoamérica (AR)
- Hamilton General Hospital (CA)
- McMaster University (CA)
- University of Washington (US)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Paris Cardiovascular Research Center (FR)
- University of Cape Town (ZA)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Werkgroep Cardiologische centra Nederland (NL)
- University of Debrecen (HU)
- University of Trieste (IT)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- Hôpital Universitaire Dupuytren (FR)
- Istituto Cardiocentro Ticino (CH)
- Danylo Halytsky Lviv National Medical University (UA)
- Foscal Hospital (CO)
- National Research Center for Preventive Medicine (RU)
- Carol Davila University of Medicine and Pharmacy (RO)
- Institutul de Urgenţă pentru Boli Cardiovasculare "Prof.Dr. C.C. Iliescu" (RO)
- Corresponding author
- Anand, Sonia S
- ORCID
- Anand, Sonia S
- Bosch, Jackie
- Eikelboom, John W
- Connolly, Stuart J
- Kakkar, Ajay K
- Keltai, Katalin
- Maggioni, Aldo P
- Störk, Stefan
- Zhu, Jun
- O'Donnell, Martin
- Fox, Keith A A
- Bhatt, Deepak L
- Misselwitz, Frank
- Vanassche, Thomas
- Leong, Darryl P
- Bangdiwala, Shrikant I
- Hart, Robert G
- Yusuf, Salim
- SCHYGIEL, PABLO OMAR
- COSTABEL, JUAN PABLO
- MACIN, STELLA MARIS
- GRINFELD, DIEGO
- VERHAMME, PETER
- DEBONNAIRE, PHILIPPE
- VRANCKX, PASCAL
- ELEGEERT, IVAN
- HOFFER, ETIENNE
- MANENTI, EULER
- REIS, GILMAR
- HERNANDES, MAURO
- TANAJURA, LUIZ FERNANDO
- TYTUS, RICHARD
- LONN, EVA
- LAMY, ANDRE
- NOISEUX, NICOLAS
- BAINEY, KEVIN
- DAGENAIS, GILLES R
- NGUYEN, MICHEL
- GUZMAN, RANDOLPH
- KHAYKIN, YAARIV
- GOSSELIN, GILBERT
- HUYNH, THAO
- ROY, ANNIE
- JIA, KAIYING
- WU, SHULIN
- ZHANG, JIWEI
- GE, JUNBO
- FU, GUOSHENG
- VESGA, BORIS
- LUBANDA, JEAN-CLAUDE
- MOTOVSKA, ZUZANA
- BRANNY, MARIAN
- HOMZA, MIROSLAV
- BRTKO, MIROSLAV
- DUARTE, YAN CARLOS
- SANCHEZ, MAYRA
- TUOMILEHTO, JAAKKO
- KANTOLA, ILKKA
- LECLERCQ, FLORENCE
- BOCCARA, FRANCK
- MESSAS, EMMANUEL
- SEVESTRE, MARIE ANTOINETTE
- CAYLA, GUILLAUME
- MOTREFF, PASCAL
- STELLBRINK, CHRISTOPH
- OPITZ, CHRISTIAN
- NIKOL, SIGRID
- SCHELLONG, SEBASTIAN
- DAVIERWALA, PIROZE
- VORPAHL, MARC
- KORANYI, LASZLO
- MURPHY, ANDREW
- MAHON, NIALL
- HALABI, MAJDI
- ZELTSER, DAVID
- KATZ, AMOS
- ATAR, SHAUL
- FAGGIANO, POMPILIO
- ROBBA, DEBORA
- MOS, LUCIO
- SINAGRA, GIANFRANCO
- GULIZIA, MICHELE MASSIMO
- GALVANI, MARCELLO
- PERNA, GIAN PIERO
- OZAKI, YUKIO
- HIGASHIUE, SHINICHI
- HOSOKAWA, SHINOBU
- FUJII, KENSHI
- KIMURA, KAZUO
- HIGUCHI, YOSHIHARU
- NODA, TOSHIYUKI
- HIRAYAMA, ATSUSHI
- INOKO, MORIAKI
- MANITA, MAMORU
- AKO, JUNYA
- YOSHIDA, TETSURO
- SHIMOMURA, HIDEKI
- KINOSHITA, NORIYUKI
- TAKAHASHI, AKIHIKO
- YUSOFF, KHALID
- KASIM, SAZZLI
- NAKANO, AKIHIKO
- NAKAMURA, SHIGERU
- SAKAMOTO, TOMOHIRO
- RONNER, EELKO
- BARTELS, GERARD
- ABOLA, MARIA TERESA
- ABAT, MARC EVANS
- JANION, MARIANNA
- GUZIK, TOMASZ
- GAJOS, GRZEGORZ
- RYNKIEWICZ, ANDRZEJ
- BRONCEL, MARLENA
- SZUBA, ANDRZEJ
- CZARNECKA, DANUTA
- SIZOVA, ZHANNA
- VOEVODA, MIKHAIL
- REPIN, ALEXEY
- EFREMUSHKINA, ANNA
- ZATEYSHCHIKOV, DMITRY
- BAE, JANG-HO
- HA, JONG-WON
- MOOE, THOMAS
- DELLBORG, MIKAEL
- ALBERTSSON, PER
- WAHLGREN, CARL-MAGNUS
- MOCCETTI, TIZIANO
- PARKHOMENKO, ALEXANDER
- TSELUYKO, VIRA
- KOVAL, OLENA
- BAZYLEVYCH, ANDRIY
- KARPENKO, OLEKSANDR
- MALYNOVSKY, YAROSLAV
- COTTON, JAMES
- CONNOLLY, DEREK
- DAVEY, PATRICK
- SENIOR, ROXY
- PEACE, AARON
- AUSTIN, DAVID
- SRIVASTAVA, SUNNY
- SHAMMAS, NICOLAS
- GURBEL, PAUL
- BANERJEE, SUBHASH
- MEHTA, RAJENDRA
- GILLESPIE, EVE
- HAMROFF, GLENN
- LADER, ELLIS
- KOSTIS, JOHN B.
- BITTNER, VERA
- CHILTON, ROBERT
- COMEROTA, ANTHONY
- BAKAEEN, FAISAL
- AMERENA, JOHN
- ROYSE, ALISTAIR
- SELVANAYAGAM, JOSEPH
- JANSEN, SHIRLEY
- HAMMETT, CHRISTOPHER
- POULTER, ROHAN
- NARASIMHAN, SESHASAYEE
- GISLASON, GUNNAR
- HOULIND, KIM
- DIXEN, ULRIK
- REFSGAARD, JENS
- PELLA, DANIEL
- SINESCU, CRINA
- BENEDEK, IMRE
- BOBESCU, ELENA
- DOBREANU, DAN
- IANCU, ADRIAN
- LIGHEZAN, DANIEL
- PETRESCU, LUCIAN
- TESLOIANU, DAN
- CHIONCEL, OVIDIU
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 391
- Issue
- 10117
- Pages
- 219-229
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4229536675
- Semantic Scholar
- af705d340539758c05004e20b5429bd9700e2fc2
- Cited by
- 879
- References
- 30
- Citations by year
- 2026: 52 · 2025: 62 · 2024: 74 · 2023: 99 · 2022: 109 · 2021: 139 · 2020: 152 · 2019: 112 · 2018: 74
- FWCI
- 72.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Arrow@dit (Dublin Institute of Technology) (submittedVersion)
- HAL (submittedVersion)
- ARAN (University of Galway Research Repository) (Ollscoil na Gaillimhe – University of Galway) (submittedVersion, cc-by-nc-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Lirias (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- rivaroxaban, aspirin, peripheral arterial disease, carotid artery disease, coronary artery disease, major adverse limb events, major amputation, cardiovascular mortality, myocardial infarction, stroke, antiplatelet therapy, direct oral anticoagulants, ankle-brachial index, intermittent claudication, asymptomatic carotid stenosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review